f Alzheimer's Disease Drug Development

References

1. 2024 Alzheimer’s Disease Facts and Figures Alzheimers Dement.20242053708–382110.1002/alz.13809
   [Google Scholar]
2. CummingsJ. LeeG. RitterA. SabbaghM. ZhongK. Alzheimer’s disease drug development pipeline: 2020 . Alzheimers Dement. Transl. Res. Clin. Interv.202061e1205010.1002/trc2.12050
   [Google Scholar]
3. JeremicD. Navarro-LópezJ. D. Jiménez-DíazL. Efficacy and Safety of Anti-Amyloid-β Monoclonal Antibodies in Current Alzheimer’s Disease Phase III Clinical Trials: A systematic review and interactive web app-based meta-analysis Ageing Res. Rev20239010201210.1016/j.arr.2023.102012
   [Google Scholar]
4. Van DyckC. H. SwansonC. J. AisenP. BatemanR. J. ChenC. GeeM. KanekiyoM. LiD. ReydermanL. CohenS. FroelichL. KatayamaS. SabbaghM. VellasB. WatsonD. DhaddaS. IrizarryM. KramerL. D. IwatsuboT. Lecanemab in early Alzheimer’s disease . N. Engl. J. Med.202338819–2110.1056/NEJMoa2212948
   [Google Scholar]
5. SimsJ.R. et al. Donanemab in early symptomatic Alzheimer disease: The trailblazer-ALZ 2 randomized clinical trial JAMA2023330651210.1001/jama.2023.13239
   [Google Scholar]
6. PanzaF. SolfrizziV. DanieleA. LozuponeM. Passive tau-based immunotherapy for tauopathiesIn Handbook of Clinical Neurology Elsevier2023 Vol. 196611–61910.1016/B978‑0‑323‑98817‑9.00029‑6
   [Google Scholar]
7. LueL.-F. BeachT.G. WalkerD.G. Alzheimer’s disease research using human microglia Cells20198883810.3390/cells8080838
   [Google Scholar]
8. HunjanG. AranK.R. Postbiotics as a therapeutic tool in Alzheimer’s disease: insights into molecular pathways and neuroprotective effects Ageing Res. Rev.202510268510.1016/j.arr.2025.102685
   [Google Scholar]
9. WangS. LiaoZ. ZhangQ. HanX. LiuC. WangJ. Mitochondrial dysfunction in Alzheimer’s disease: A key frontier for future targeted therapies Front. Immunol.202515148437310.3389/fimmu.2024.1484373
   [Google Scholar]
10. KshirsagarS. SawantN. MortonH. ReddyA.P. ReddyP.H. Retracted: Protective effects of mitophagy enhancers against amyloid beta-induced mitochondrial and synaptic toxicities in Alzheimer disease Hum. Mol. Genet.,2022313423-43910.1093/hmg/ddab262
    [Google Scholar]
11. MeijerL. ChrétienE. RavelD. Leucettinib-21, a DYRK1A kinase inhibitor as clinical drug candidate for Alzheimer’s disease and Down syndrome J. Alzheimers Dis.2024101s1S95–S11310.3233/JAD‑240078
    [Google Scholar]
12. AhmadS.R. ZeyaullahMd. KhanM.S. AlShahraniA.M. AltijaniA.A.G. AliH. DawriaA. MohieldinA. AlamM.S. MohamedA.O.A. Pharmacogenomics for neurodegenerative disorders - A focused review Front. Pharmacol.202415147896410.3389/fphar.2024.1478964
    [Google Scholar]